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Reproductive Genetics and Epigenetics (R21)
The purpose of this Funding Opportunity
Announcement (FOA) issued by the National
Institute of Child Health and Human Development
(NICHD), National Institutes of Health (NIH), is
to continue to support new studies on the genes and
genetic and epigenetic mechanisms influencing sex
determination, fertility, reproductive health and
reproductive aging, and other topics in Reproductive
Genetics and Epigenetics. Studies submitted under
this FOA are expected to identify and characterize
the relevant genes, determine their function in nor-
mal human reproduction and reproductive develop-
ment, identify functional partners or pathways and
the nature of the interactions, and further our under-
standing of the consequences of mutations or dysreg-
ulation for human reproductive health. Studies of
animal models are integral to this effort and are
encouraged along with studies involving human sub-
jects.
With the completion of the human genome
project, the focus of genetic research must shift to
functional genomics. NICHD encourages scientists
interested in reproduction to lead the way in deter-
mining the genes and their mechanisms of action
involved in the development of the gonads, repro-
ductive ducts, and genitalia, the processes of game-
togenesis, normal and premature reproductive
aging, and reproductive disorders such as infertility,
cryptorchidism, endometriosis, and polycystic ovar-
ian syndrome (PCOS). Studies on the genetic epi-
demiology of reproductive disorders might begin
with the collection of large numbers of affected
patients and their relatives for linkage analysis, asso-
ciation studies or quantitative trait loci (QTL)
analysis. Studies using innovative statistical or tech-
nical methods are highly encouraged. We also
encourage research into epigenetic mechanisms crit-
ical to reproduction, especially areas such as the
establishment and maintenance of methylation pat-
terns or imprinted loci in the early embryo, the tim-
ing, mechanisms, and role of genomic methylation
in gametogenesis, the effects of assisted reproduc-
tive therapy (ART) on imprinting and genomic
methylation, and the reproductive determinants
and consequences of X-chromosome inactivation.
Reproductive genetics is a broad research area,
and the topics discussed and listed below are not
meant to be exclusive areas of interest, but rather a
sampling of the types of problems that this FOA
intends to address.
The genetics of sex determination. Sex determi-
nation is the translation of the chromosomal sex
(XX or XY) into the gender-appropriate internal
and external reproductive structures. The initial
events of sex determination are, therefore, geneti-
cally determined. Errors in the process can range in
severity from complete sex reversal to gonadal dys-
genesis or minor genital abnormalities. Sex determi-
nation, as an early embryological event, can help us
address basic questions of the regulation of gene
expression, cell-fate determination, and hormone
signaling.
Approximately one in 1,000 newborns has
some abnormality of genital and/or gonadal devel-
opment. In many cases, gonadal dysgenesis is part
of a larger pathologic syndrome, such as Frasier syn-
drome, Deny-Drash syndrome, or campomelic dys-
plasia, to name a few. The known genes involved in
sex determination often act as growth and/or differ-
entiation factors, and there is mounting evidence
that they may be important in tumorigenesis in the
gonads as well as other tissues.
Despite the identiﬁcation of the Y-chromosome
gene SRY as the testis-determining factor almost 15
years ago, the mechanisms and pathways of normal
sex differentiation are still not well understood. In
particular, although some downstream effects of
SRY are known, such as cellular proliferation, Sertoli
cell differentiation, and testis-specific vasculariza-
tion, the direct transcriptional targets of SRY remain
unknown. The factors regulating SRY expression
remain unknown as well. While genes such as SOX-
9, WT-1, DAX-1, DMRT-1, GATA4, FOG2, and
SF-1, among others, contribute to sex determina-
tion, the nature and timing of their interactions
remain unclear, and there are clearly other unknown
genes to be identiﬁed. A further level of complexity
arises with gene dosage effects, such as XY sex rever-
sal caused by duplication of Dax-1.
Sex determination can be divided into steps
consisting of establishment of the bipotential
gonad, formation of the primordial gonad, and dif-
ferentiation of the gonad. Many of the sex deter-
mining genes act in multiple steps, but SRY mainly
functions in shaping the primordial gonad into a
testis. However, the classic view of SRY as a switch
that confers maleness is an over-simplification as
illustrated by the enormous potential for ambiguity
in sex determination, and by evidence suggesting
that steps in testis development that were once
thought to be tightly coordinated, such as
mesonephric cell migration and Leydig cell differ-
entiation, or the formation of testis cords and the
inhibition of male germ cell meiosis, can occur
independently of each other. Additionally, ovarian
development may not be the passive default process
it was once thought to be. Estrogen may be neces-
sary to maintain the ovarian phenotype, as mice
unable to make estrogen (ArKO mice) or bind
estrogen develop patches of Sertoli and Leydig cells
within their ovaries postnatally.
Germ cells play a critical role in the formation
of ovaries, although testes can form in their
absence. The germ cells migrate into the gonad
through the gut, through a process which has yet to
be fully characterized. The presence of meiotic
germ cells is critical for the formation and mainte-
nance of ovarian follicles, while in contrast, in
males the testis cords surround the germ cells and
meiosis is inhibited. Germ cell migration and the
progression into meiosis are not well understood.
There is clear evidence that the genes involved
in sex determination have important roles beyond
gonadal fate. Some, such as WT-1, are expressed in
common embryonic precursors to different organ
systems. Mutations in FOXL2, a gene deleted in
polled intersex goats, cause the human syndrome
BPES that often includes premature ovarian failure.
The antimullerian hormone, known as Amh or
MIS, causes regression of the female duct system in
normal males, and in adult males, MIS has
inhibitory effects on both Leydig cells and testos-
terone production. Such examples clearly demon-
strate that the continued study of sex determination
will not only benefit those born with gonadal dys-
genesis or ambiguous genitalia, but will also
advance our knowledge of the physiology of the
adult reproductive system, and the development
and regulation of other organ systems.
Specific topics of interest include, but are not
limited to: 1) identiﬁcation of the target genes and
processes regulated by SRY; 2) clarification of the
functional interactions between sex determining
genes; 3) cloning of genes at loci associated with sex
reversal, in humans and other species, and elucidation
of their function; these studies may entail the collec-
tion of affected families or animal models and careful
phenotypic description; 4) determination of how
germ cell migration and meiosis affect sex determina-
tion and gonadal development; 5) study of the genes
and processes regulating the retention or loss of the
Wolffian and Mullerian ducts; 6) comparing and
contrasting mammalian and nonmammalian sex
determination systems to better understand the com-
mon pathways and genes; 7) creation of new cell or
tissue culture systems, or animal models (especially
transgenic or knock-out mice), to precisely character-
ize the functions of sex-determining genes.
Genes regulating fertility, reproductive health,
and reproductive aging. Infertility is a major public
health problem in our country, affecting 10–15%
of couples, or about 2.5 million couples in the
United States. The annual cost of services to diag-
nose and combat infertility is now estimated at over
one billion dollars. In recent years, great advances
have been made in medical and surgical treatments
for infertility caused by hormonal or structural
defects. However, 30% of couples are infertile due
to idiopathic or genetic causes, and they may suffer
through failed conventional treatments before
resorting to assisted reproductive technologies
(ART) to conceive their biological children. Given
the known and potential problems associated with
the use of ART, it is essential that we focus our
efforts on identifying and treating the underlying
causes of infertility.
Studies of human infertility and studies using
animal models have revealed many single gene
mutations that cause infertility and new phenotypes
continually appear in the literature. Each new gene
teaches us more about the intricate pathways that
contribute to normal fertility and may suggest leads
for contraceptives. Epidemiological and family
studies of human infertility are now feasible with
the advent of genetic databases and new statistical
techniques.
The most common identiﬁable cause of human
male infertility is Klinefelter’s syndrome, occurring
in 1 in 400 live births. The Klinefelter’s XXY geno-
type disrupts testis development and, in combina-
tion with high levels of meiotic nondisjunction, low
sperm counts and infertility ensue. The Klinefelter’s
phenotype, along with data showing exclusive
expression of several X-chromosome genes in the
testes, suggests that the X-chromosome figures
prominently in testis physiology. Clearly, loci on
the Y-chromosome are also critical to male fertility.
Deletions within the male specific region of the
Y-chromosome, previously referred to as the non-
recombining region, are also a common genetic
cause of spermatogenic failure in men. Mutation of
speciﬁc genes within the AZF (azoospermia factor)
regions of the Y-chromosome, most notably DAZ,
severely disrupts spermatogenesis. The recent map-
ping of the male specific region of the Y-chromo-
some suggests that gene conversion (nonreciprocal
recombination), while conserving important testis
gene function on the Y-chromosome through evo-
lution, may also predispose to deletions that abolish
spermatogenesis. 
Less dramatic mutations can also render males
infertile. Disruption of the action of hypothalamic
hormones can delay or prevent puberty, leading to
oligospermia or azoospermia. Mutations causing
both the X-linked and autosomal dominant forms of
Kallmann’s syndrome (hypogonadotropic hypogo-
nadism and anosmia), which is more common in
males, were recently identiﬁed (KAL-1 and FGFR1,Fellowships, Grants, & Awards
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respectively). Similarly, mutation of the beta-sub-
unit of the gonadotropin FSH also causes infertility
by compromising spermatogenesis. Even when sper-
matogenesis proceeds smoothly, infertility can result
if the chromatin is incorrectly packaged into the
sperm head. Mutations that abolish the function of
the transition proteins or the protamines that com-
pact sperm chromatin cause infertility. The sperm
mitochondrial genome also contributes to fertility.
For example, absence of the common form of the
POLG allele, encoding a mitochondrial DNA poly-
merase, is associated with infertility in men.
Genetic conditions in which the testes them-
selves are normal, but the male tract is affected, can
render men infertile. Mutations in CFTR (the gene
causing cystic ﬁbrosis) can cause congenital bilateral
absence of the vas deferens, seen in 1% of infertile
men. Cryptorchidism is the most common defect of
newborn boys, affecting 2–3%. Strong evidence
demonstrates a genetic component to cryp-
torchidism. Mutation of the genes encoding either
INSL3 (insulin-like hormone) or its receptor
GREAT/LGR8, compromises the transabdominal
phase of testicular descent, causing cryptorchidism
which, if uncorrected, will result in infertility.
However, the known mutations explain only a
minority of cases of cryptorchidism, suggesting the
involvement of other genes and pathways.
The identification of genetic causes of female
infertility lags behind, possibly because the female
reproductive system is more complex than the male
system. Finely tuned cyclic fluctuations in hor-
mones coordinate the follicular development, ovu-
lation, and uterine receptivity for implantation, the
components that comprise a normal menstrual
cycle. This complexity suggests that there are hun-
dreds of genes, each contributing a small effect on
female fertility.
Genes involved in regulating the hypothala-
mic–pituitary–ovarian axis are obvious candidates
for female infertility and, while mutations have
been reported in the genes encoding FSH-beta and
the LH receptor, and the genes associated with
Kallmann’s syndrome have been identified, these
mutations explain only a tiny proportion of cases of
female infertility. However, work in highly proliﬁc
sheep has identiﬁed genes controlling ovulation rate
and fertility, as well as ovarian development, which
may lead to better understanding of infertility in
women. In some breeds of ewes, naturally occurring
mutations of genes encoding key players in the
transforming growth factor beta signaling pathway
increase ovulation rate and twinning. Conversely,
homozygous mutation of the gene encoding the
TGF signaling molecule BMP15 (GDF9B) causes
sterility in the same breed of sheep. Such studies
suggest new candidate molecules and pathways to
study in human fertility.
The disruption of early embryonic develop-
ment may be an underestimated cause of infertility.
Mammalian oocytes store products necessary for
the very early stages of development, until the
embryonic genome is activated. Deletion of mater-
nal oocyte products such as MATER, DNMT1o,
and Npm2 arrests embryo development and leads
to female infertility or subfertility in knockout
mice. It is not known if mutations in these genes,
or insufﬁcient levels of their products, are a cause of
human infertility.
Reproductive diseases such as endometriosis
and polycystic ovarian syndrome are common and
can be quite debilitating. Recent research indicates
genetic components to these disorders; identiﬁcation
of causative or modifying genes would be of enor-
mous benefit. Both diseases are likely to involve
complex interactions between gene products and
environment rather than single major genes.
Polymorphisms in the insulin gene, the gene
CYP11a, and the androgen receptor gene have been
associated with hyperinsulinemia and hyperandro-
genism in PCOS. Similarly, alterations in the estro-
gen receptor gene, genes encoding products involved
in detoxiﬁcation, homeobox genes, and the LH-beta
gene, have been associated with a small number of
cases of endometriosis. Comparative genomic
hybridization and gene chip studies of endometriosis
have revealed candidate regions and patterns of
altered gene expression, but no major genes as yet.
Because of the sharp decline in female fertility
with age and the increasing number of women who
opt to have children later in life, the incidence of
infertility is growing. Data from animal models and
some human syndromes indicate that the timing of
reproductive aging, in a continuum from premature
ovarian failure to early menopause and normal
menopause, may have genetic components. The
genes and mechanisms contributing to reproductive
aging have not been well characterized. Given the
social trend to delay starting a family and the con-
cerns about the prolonged use of hormone replace-
ment therapy for menopause, understanding the
mechanisms of reproductive aging is a high priority.
Premature ovarian failure (POF), deﬁned as the
cessation of menstruation before the age of 40,
affects approximately 1% of women. Most cases of
POF are assumed to be genetic and insight into this
condition may help us better understand the varia-
tion in normal ovarian aging as well. Although the
mechanism is not known, mutations in the gene
encoding the FSH receptor are a rare cause of POF.
Women carrying the fragile X premutation have a
greater risk for premature ovarian failure,  Mutation
in a forkhead transcription factor, FOXL2 (3q23),
causes autosomal dominant POF due to follicle
depletion in some women affected with the syn-
drome BPES. FOXL2 mutation results in ovarian
phenotypes ranging from streak ovaries to otherwise
normal ovaries that lack adequate follicles. Mice
lacking FOXO3A, a distant relative of FOXL2,
show early depletion of ovarian follicles and sterility
shortly after sexual maturity. Other causative genes
for POF in women, and perhaps protective genes or
alleles, remain to be identiﬁed.
The accumulation of meiotic errors in aging
oocytes contributes strongly to the age-related
decrease in women’s fertility and the increased risk
for chromosomal abnormalities in children born to
older mothers. This may be due to the unusual
robustness of oocytes to proceed through meiosis
despite ﬂaws in the process; there are multiple exam-
ples of greater tolerance of meiotic defects in oogene-
sis as compared to spermatogenesis. For example,
male germ cells are unable to progress through meio-
sis when the synaptonemal complex, which helps to
hold homologous chromosomes together during
meiosis, is compromised. While male mice bred to
lack synaptonemal complex protein 3 are infertile,
female SCP-3 knockout mice, though subfertile, are
able to reproduce. Because the phenotype of subfer-
tility due to embryo wastage becomes more severe
with age, these mice may be a good model system
not only for delineating the differences in meiosis in
male and female gametes, but also for delineating the
interactions between infertility and aging.
The phenomenon of reproductive aging in
men, or decreased fertility with male age, is under
debate and deﬁnitive studies are needed. Studies in
old male rats demonstrate decreased fertility and an
increased risk of siring abnormal offspring.
Mutation rates appear to increase with age in male
gametes and some genetic diseases, including both
recessive X-linked and autosomal dominant condi-
tions, demonstrate a paternal age effect, suggesting
that the process of spermatogenesis does change
with age in men. This is a phenomenon that needs
further characterization and mechanistic study.
Specific topics of interest include, but are not
limited to: 1) identifying specific Y-chromosome
genes responsible for oligospermia or azoospermia,
and establishing their functions in spermatogenesis;
2) identification of major genes, gene interactions
or QTLS involved in regulating female fertility or
ovarian or uterine function; 3) investigations of the
heritability of infertility in offspring conceived
through ART; 4) studies of the genetic mechanisms
that establish the pool of primordial follicles and
subsequent follicle development or loss; 5) identiﬁ-
cation of the gene mutations underlying inherited
disorders of the reproductive organs or tract, such
as PCOS, endometriosis, premature ovarian failure,
and cryptorchidism, using candidate gene
approaches as well as genetic epidemiology and
linkage and/or association studies; 6) studies to elu-
cidate the processes and mechanisms of the conden-
sation and decondensation of the paternal and
maternal genomes during gametogenesis and
embryogenesis; 7) studies of the mechanisms
responsible for the accumulation of meiotic errors
in aging oocytes and identification of factors that
impede or advance the process; 8) studies of similar-
ities and differences in male and female meiosis,
and how those contribute to the differential toler-
ance for meiotic errors; implications for fertility and
contraception.
Genomic imprinting and X-chromosome inacti-
vation. The wealth of gene sequence data generated
by the Human Genome Project will significantly
improve our ability to detect and treat genetic dis-
eases. However, diseases caused by epigenetic
defects, such as improper gene methylation or
improper X-chromosome inactivation, clearly
demonstrate that in addition to a normal gene
sequence, the timing, specificity, degree of gene
expression, and even the parental origin of an allele
are critical to normal human development and con-
tinued health. The epigenetic processes of imprint-
ing and X-inactivation are intimately tied to
reproduction, as the patterns are established during
gametogenesis and embryogenesis, and they may in
turn affect embryogenesis, gonadal/genital develop-
ment, and fertility.
Imprinting is the phenomenon whereby one of
the two autosomal alleles is preferentially expressed,
dependent on its parental origin. Current estimates
suggest that > 1% of all human genes are
imprinted. Imprints are thought to be encoded by
gene methylation patterns that differ between the
maternally and paternally derived alleles. Parental
imprints from the previous generation are erased in
the germ cells at an early stage of development and
new sex-specific imprints are established. This
appears to occur before the onset of meiosis in male
germ cells, but maternal imprints are established
later, in growing oocytes arrested at the diplotene
stage. Interestingly, the imprints are not all imposed
together, as different genes are marked at various
stages of oocyte growth. Although a genome-wide
wave of demethylation occurs before implantation
and de novo methylation reestablishes the patternshortly after implantation, the core regions of the
imprinted genes are somehow protected from these
changes. Imprinting centers may play a role in the
establishment and maintenance of the appropriate
parental imprint, although the mechanism of such
events remains unclear. Many imprinted loci
encode anti-sense transcripts that have been impli-
cated in the initiation of genomic imprinting, as
well as X-chromosome inactivation.
Many key molecules regulating genomic
methylation and transcriptional silencing have been
identified. Methylation generally silences allele
expression, as methyl-CpG-binding proteins such as
MeCP2, bind to methylated DNA and recruit his-
tone deacetylases. Hypoacetylated DNA is presum-
ably inactive because it is conformationally
inaccessible to the transcription machinery. The
establishment and maintenance of DNA methyla-
tion are regulated by the DNA methyltransferases
(Dnmt). Dnmt3A and Dnm3B function in de novo
methylation, while Dnmt1 maintains methylation
after each round of replication. Deficiency of
Dnmt1 is lethal to embryos due to genome-wide
demethylation. In contrast, the oocyte-specific
form, Dnmt1o, seems to act only on certain genes
and only at the eight-cell stage. Dnmt3L is required
for the establishment of imprints during oogenesis,
but is not necessary for the maintenance of paternal
imprints during embryogenesis. BORIS, a paralog
of CTCF, may participate in the erasure of parental
methylation marks in the male germ line. More
studies are needed to determine how the methyla-
tion and demethylation machinery correctly recog-
nizes imprinted regions, discriminates between the
maternal and paternal marks, and establishes or
maintains the appropriate methylation patterns dur-
ing gametogenesis and early embryogenesis.
Methylation of histones, in addition to DNA
methylation, may regulate gene expression and the
read-out of these types of methylation signals
remains unclear. In mice lacking the polycomb
group gene Eed, a subset of paternally repressed
genes is improperly activated and expressed. Such
data suggest that other transacting factors form an
additional layer of regulation of the expression of
imprinted genes.
Several human syndromes, such as Rett syn-
drome, ICF, Beckwith-Weidemann syndrome,
Prader-Willi syndrome, and Angelman syndrome,
are caused by defects in imprinting or in DNA
methylation. Dysregulation of imprinted genes
often manifests as abnormal growth of the fetus or
placenta. One recently discovered example is the
unknown locus on chromosome 19q13.4 that
causes recurrent biparental complete hydatidiform
molar pregnancies, as maternal alleles acquire pater-
nal methylation patterns. Studies suggest that a fail-
ure of epigenetic reprogramming, as evaluated by
methylation patterns, may underlie the extraordi-
narily high failure rate of cloning by nuclear trans-
fer. The findings that cloned mouse embryos
aberrantly express Dnmt1, while Dnmt1o fails to
translocate to the nucleus, provide further support
for this hypothesis. Culture conditions can also sig-
nificantly and selectively alter the expression of
imprinted genes, a finding that may be critical to
human in vitro fertilization protocols. There is a
trend among ART clinics to culture embryos for
longer periods to enable selection of higher quality
embryos; it is not clear if loss of imprinting occurs
in such conditions and, if so, what effect it might
have on the offspring. It seems likely that other
more subtle phenotypes will be linked to defects in
imprinting or DNA methylation/demethylation as
well; exploration of these processes specifically in
reproductive tissues is encouraged.
The inactivation of one X-chromosome in
females is another type of gene silencing that acts as
dosage compensation for the XX vs. XY genotype.
Some critical X-linked genes "escape" inactivation
and are expressed from both copies of the X-chro-
mosome. Turner syndrome, resulting from a 45, 
X karyotype, clearly demonstrates the importance of
genes on the second X-chromosome for fetal sur-
vival, as well as ovarian development.
There are two basic processes in X-inactivation:
choice of which X-chromosome to inactivate, and
implementation of the silencing. While recent stud-
ies show that X-inactivation has some mechanistic
similarities to autosomal imprinting, X-chromo-
some inactivation in the embryo is usually random
so that in each cell, the maternally and paternally-
derived X-chromosome have an equal probability of
inactivation. The molecule Xist, an X-encoded
untranslated RNA, is the master regulator of X-
chromosome inactivation. Xist is expressed only
from the X-chromosome destined to become inac-
tive (X-I). The Xist transcripts coat X-I in cis and
soon after, histone 3 is methylated on lysine 9 on
the inactive X. The X-chromosome that is destined
to remain active (X-A) is protected from Xist by
Tsix, the Xist antisense transcript. On X-A, histone
3 is methylated on lysine 4; this differential methy-
lation suggests that a histone code may regulate the
transcriptional status of the X-chromosome. The
DNA of the inactive X-chromosome is hypermethy-
lated and this is functionally significant as Dnmt1
mutant embryos fail to maintain random X-chro-
mosome inactivation. Other events that mediate the
silencing of the Xist-coated X-chromosome remain
unknown. Recent data also suggest that there is
active selection of both X-I and X-A, rather than
one chromosome’s state being conferred by default.
Although the choice of which X-chromosome
to inactivate is random in the embryo, it is
imprinted in the extra-embryonic cells of mammals:
the paternal X (Xp) chromosome is preferentially
inactivated. The mechanisms for imprinted silenc-
ing of Xp in the extra-embryonic tissue and random 
X-chromosome inactivation in the embryo seem to
be quite different. For example, Dnmt1 mutant
embryos fail to maintain random X-chromosome
inactivation in the embryo, but Xp is correctly inac-
tivated in the extra-embryonic cells. Also, homozy-
gous mutant eed mice initiate but fail to maintain
imprinted Xp inactivation in the trophectoderm,
but maintain normal random X-chromosome inac-
tivation in the embryo itself, suggesting that eed
functions only in maintenance of imprinted, but
not random, X-chromosome inactivation.
Normal X-chromosome inactivation is essential
to reproduction. Appropriate imprinted X-inactiva-
tion is critical to formation of the trophoblast and,
ultimately, the placenta. Both heterozygous and
homozygous Tsix knockout females are subfertile,
with homozygous females showing a more drastic
loss of fertility. Similar to imprinting defects in
cloned embryos, cloned or in vitro embryos show
disruption of dosage compensation of X-linked
genes that may affect embryonic development.
The presence of skewed X-chromosome inacti-
vation (XCI), usually deﬁned as > 90% inactivation
of a particular one of the pair of X-chromosomes, is
increased in women with recurrent spontaneous
abortion. In addition, women with skewed XCI and
recurrent spontaneous abortion are more likely to
have trisomic losses than women without XCI, but
experiencing recurrent spontaneous abortion.
Finally, deviations from random choice in X-chro-
mosome inactivation can affect the relative expres-
sion of X-linked genes, many of which act in
reproduction.
Transcriptional silencing of the X-chromosome
(as well the Y-chromosome) occurs in males as well,
just before meiotic prophase in spermatogenesis.
The mechanism of male X-chromosome inactiva-
tion is likely completely different from that in the
female because Xist mutation does not prevent the
silencing in males. This remains a very poorly
understood area.
Specific topics of interest include, but are not
limited to: 1) identifying genes and mechanisms
important in erasing and reestablishing genomic
imprinting and genome-wide methylation during
gametogenesis and early embryonic development;
2) characterizing the effects of manipulations of
gametes or fertilized eggs, especially procedures
commonly used in assisted reproductive technology,
on gene methylation patterns, imprinting or
X-inactivation; 3) investigation of defects in
imprinting or methylation patterns in abnormal
reproductive phenotypes including effects on game-
togenesis, fertility, or gonadal differentiation and
development; 4) description of the effects of muta-
tions of the imprinting machinery in gametes and
reproductive tissues, and on early embryonic devel-
opment; 5) elucidation of the mechanism of the
reversal of X-inactivation in XX primordial germ
cells; 6) identiﬁcation of the nature of the imprinting
mark of the paternal X-chromosome and the mecha-
nisms of imprinted X-inactivation in extra-embry-
onic cells; 7) studies of the biological signiﬁcance and
the mechanisms leading to X-chromosome inactiva-
tion in male meiotic germ cells; 8) studies of possible
associations between skewed X-inactivation and vari-
ous reproductive tract development and function,
whether having protective or deleterious effects.
This funding opportunity will use the NIH
Exploratory/Developmental Research Grant (R21)
award mechanism. As an applicant, you will be
solely responsible for planning, directing, and exe-
cuting the proposed project. 
This funding opportunity uses just-in-time
concepts. It also uses the modular budget formats
(see the Modular Applications and Awards section
of the NIH Grants Policy Statement). Specifically,
if you are submitting an application with direct
costs in each year of $250,000 or less (excluding
consortium Facilities and Administrative [F&A]
costs), use the PHS398 Modular Budget compo-
nent provided in the SF424 (R&R) Application
Package and SF424 (R&R) Application Guide
(see specifically Section 5.4, Modular Budget
Component, of the Application Guide).
The R21 mechanism is intended to encourage
new exploratory and developmental research pro-
jects and/or exploration of novel hypotheses and
strategies. For example, such projects could assess
the feasibility of a novel area of investigation or a
new experimental system. These projects should be
exploratory and novel, and distinct from the type of
project supported through the traditional R01. For
further information on the R21 mechanism, see:
http://grants2.nih.gov/grants/funding/r21.htm.  
Exploratory/developmental grant support is for
new projects only; competing renewal (formerly
competing continuation) applications will not be
accepted. Up to two resubmissions (formerly revi-
sions/amendments) of a previously reviewed
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submitted. See NOT-OD-03-041, May 7, 2003. 
Applicants must download the SF424 (R&R)
application forms and SF424 (R&R) Application
Guide for this FOA through Grants.gov/Apply.
Note: Only the forms package directly attached
to a speciﬁc FOA can be used. You will not be able
to use any other SF424 (R&R) forms (e.g., sample
forms, forms from another FOA), although some of
the Attachment ﬁles may be useable for more than
one FOA. For further assistance contact GrantsInfo,
301-435-0714 (telecommunications for the hearing
impaired: TTY 301-451-0088) or by e-mail:
GrantsInfo@nih.gov.
Prepare all applications using the SF424 (R&R)
application forms and in accordance with the SF424
(R&R) Application Guide (MS Word or PDF).
The SF424 (R&R) Application Guide is criti-
cal to submitting a complete and accurate applica-
tion to NIH. There are fields within the SF424
(R&R) application components that, although not
marked as mandatory, are required by NIH (e.g.,
the Credential log-in field of the Research &
Related Senior/Key Person Proﬁle component must
contain the PD/PI’s assigned eRA Commons User
ID). Agency-speciﬁc instructions for such ﬁelds are
clearly identified in the Application Guide. For
additional information, see Tips and Tools for
Navigating Electronic Submission on the front page
of Electronic Submission of Grant Applications.
The SF424 (R&R) application is comprised of
data arranged in separate components. Some com-
ponents are required, others are optional. The
forms package associated with this FOA in
Grants.gov/APPLY will include all applicable com-
ponents, required and optional. A completed appli-
cation in response to this FOA will include the
following components: 1) SF24 (R&R) (cover com-
ponent); 2) research and related project/perfor-
mance site locations; 3) research and related other
project information; 4) research and related
senior/key person; 5) PHS398 cover page supple-
ment; 6) PHS398 research plan; 7) PHS398 check-
list; 8) PHS398 modular budget.
The application submission dates for this PA
are available at http://grants.nih.gov/grants/fund-
ing/submissionschedule.htm. The complete version
of this PA is available at http://grants.nih.gov/
grants/guide/pa-ﬁles/PA-06346.
Contact: Susan Taymans, Reproductive
Sciences Branch, Center for Population Research,
National Institute of Child Health and Human
Development, 6100 Executive Boulevard, Room
8B01, Bethesda, MD 20892-7510, 301-496-6517,
fax: 301-496-0962, e-mail: Taymanss@
mail.nih.gov. Reference PA-06-346.
Integrating Lung Genetics and Genomics in
Human Populations (R01) 
Over the past few years, compelling evidence (in
mouse, yeast, and a few human studies) has demon-
strated the power of integrating genotypic and gene
expression data to accelerate gene discovery.
Potentially, it represents a more powerful way to
understand the relationship of genes to human com-
plex traits. This will require linking expression array
technology, genotyping technology, bioinformatics,
and genetic statistics in innovative ways and apply-
ing these methodologies to clinical phenotypes to
identify genes and predict clinical outcomes.
Examples of this would be the use of expression pro-
ﬁles as the basis for phenotypes for linkage analysis
or the use of expression profiles with SNP associa-
tion data to predict clinical outcomes. Presently,
these recent developments that accelerate gene ﬁnd-
ing have not been applied to the lung because inves-
tigators are exploring these as separate disciplines.
Investigators know how to do one or the other of
these types of experiments, but not both, hindering
the integration of these approaches. This program
announcement seeks to provide an important stimu-
lus to bring these complementary ﬁelds together to
more rapidly identify genes associated with lung dis-
ease and more efﬁciently identify the gene networks
associated with health and disease in the lung.
This is important because it remains difﬁcult to
identify genes related to complex trait phenotypes
in the lung. Utilizing expression and association
together will make identifying genes and gene path-
ways much easier. It will be easier because expres-
sion is a complementary technology to association
that can validate association findings and demon-
strate novel relationships among genes. Since genes
work together with other genes in pathways, ﬁnding
the critical interrelationships is important. In addi-
tion, expression can be used to define subpheno-
types of disease that can then be used for clinical
prediction in association studies. Identifying these
genes is the ﬁrst step to developing models that will
better predict disease natural history, disease risk,
response to therapy, and risk of hospitalization.
Prediction has proceeded faster in other disease
areas than in lung disease, such as cancer, because of
the use of gene arrays on tumor tissue. No lung dis-
ease area has yet combined arrays with genotyping
and genetic association. If successful, it will fuel
translational research that will bring the human
genome project to the clinical arena much faster.
Bringing expression and genetic association together
in studies of lung disease will internally validate
gene targets, enhance linkage and association analy-
sis, assist in describing epistatic interactions, and
define new pathways. Thus, it will advance the
agenda for predictive medicine, which is one of the
translational goals of the human genome project
and an important goal of the NHLBI. 
The completion of the human genome project
and the development of high-throughput technolo-
gies such as gene-chip and rapid SNP genotyping
greatly facilitate the search for genes that contribute to
disease variability and disease risk. The purpose of this
initiative is to stimulate innovative approaches to
merge genetic and genomic techniques to ﬁnd genes
associated with human complex traits for lung disease.
Research topics to be addressed as part of this
initiative include, but are not limited to: 1) studies
that integrate linkage and association data with gene
expression data to identify novel loci related to dis-
ease pathogenesis, disease severity, or response to
drug therapy (pharmacogenetics); 2) studies that
integrate gene expression data with cross-sectional
and longitudinal quantitative or discrete clinical
phenotypes as a means to identify novel gene targets
and pathways, and to refine phenotype definitions
based on expression proﬁles; 3) studies that develop
clinical prediction models based on combinations of
genetic (genotype) data with gene expression proﬁl-
ing; 4) genome-wide association results correlated
with genome-wide expression results to determine
overlap at the genome level; 5) studies that use
genomic applications to conﬁrm or validate the pos-
sible genotype-phenotype associations in complex
traits; 6) studies that develop new statistical or
bioinformatics approaches to the analysis of large
amounts of genetic and genomic data.
It would be expected that investigators would
have the population in hand, and either DNA or
RNA or relevant cells to respond to this PA.
However, collection of either DNA or RNA or cells
would be permissible under this PA. Groups expert
in genetics or genomics are encouraged to collabo-
rate with each other to accomplish the goals of this
PA. Since expression is tissue speciﬁc, investigators
must demonstrate the relevance of the cells being
used for expression to the lung disease of interest.
These approaches are not exclusive and investigators
are encouraged to consider novel methods as to how
they would apply genetic (genotype) and genomic
(expression) technologies to address important
unsolved clinical questions of relevance to human
lung disease.
This funding opportunity will use the R01
award mechanism. As an applicant, you will be
solely responsible for planning, directing, and exe-
cuting the proposed project. 
This funding opportunity uses just-in-time
concepts. It also uses the modular as well as the
nonmodular budget formats (see http://grants.nih.
gov/grants/funding/modular/modular.htm).
Specifically, if you are submitting an application
with direct costs in each year of $250,000 or less,
use the modular budget format described in the
PHS 398 application instructions. Otherwise follow
the instructions for nonmodular research grant
applications.
The PHS 398 application instructions are
available at http://grants.nih.gov/grants/funding/
phs398/phs398.html in an interactive format.
Applicants must use the currently approved version
of the PHS 398. For further assistance contact
GrantsInfo, 301-435-0714 (telecommunications for
the hearing impaired: TTY 301-451-0088) or by e-
mail: GrantsInfo@nih.gov.
Applications must be prepared using the most
current PHS 398 research grant application instruc-
tions and forms. Applications must have a D&B
Data Universal Numbering System (DUNS) num-
ber as the universal identiﬁer when applying for fed-
eral grants or cooperative agreements. The D&B
number can be obtained by calling 866-705-5711
or through the web site at http://www.dnb.com/us/.
The D&B number should be entered on line 11 of
the face page of the PHS 398 form. 
The application submission dates for this PA
are available at http://grants.nih.gov/grants/fund-
ing/submissionschedule.htm. The complete version
of this PA is available at http://grants.nih.gov/
grants/guide/pa-ﬁles/PA-06-370.
Contacts: Susan Banks-Schlegel, Division of
Lung Diseases, National Heart, Lung, and Blood
Institute, Two Rockledge Center, Suite 10018,
6701 Rockledge Drive, Bethesda, MD 20892-7952
USA, 301-435-0202, fax: 301-480-3557, e-mail:
Schleges@nih.gov; Dorothy Gail, Division of Lung
Diseases, National Heart, Lung, and Blood
Institute, Two Rockledge Center, Suite 10018,
6701 Rockledge Drive, Bethesda, MD 20892-7952
USA, 301-435-0222, fax: 301-480-3557, e-mail:
Gaild@nhlbi.nih.gov. Reference PA-06-370.
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